ViglinoG., CancariniG.C., CatizoneL.Ten years experience of CAPD in diabetics: Comparison of results with non-diabetics.Nephrol Dial Transplant1994; 9: 1443–8.
LameireN., MatthysD., MatthysE., BeheydtR.Effect of long-term CAPD on carbohydrate and lipid metabolism.Clin Nephrol1988; 30(Suppl 1): S53–8.
4.
RizzaR.A., GerichJ.E., ServiceF.J.Control of blood sugar in insulin-dependent diabetes. Comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional insulin therapy.N Engl J Med1980; 303: 1313–18.
5.
SchadeD.S., EatonR.P., FriedmanN.M., SpenserW.J.Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man.Diabetologia1980; 19: 35–9.
6.
NelsonJ.A., StephenR., LandouS.T.Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized swine.Metabolism1982; 31: 369–72.
7.
RizzaR.A., MandarinoL.J., GenestJ.Production of insulin resistance by hyperinsulinemia in man.Diabetologia1985; 28: 70–5.
8.
PyoralaK., SavolainenE., KaukolaS., HaapakoskiJ.Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9½ year follow up of the Helsinki policemen study population.Acta Med Scand1985; 701(Suppl): 38–52.
9.
RubensteinA.H., PottengerL.A., MakoM.The metabolism of proinsulin by the liver.J Clin Invest1972; 51: 912–16.
10.
FalholtK., CutfieldR., AlejandroR.Influence of portal delivery of insulin on intracellular glucose and lipid metabolism.Metabolism1991; 40: 122–6.
11.
SchadeD.S., HeatonR.P.The peritoneum a potential insulin delivery route for a mechanical pancreas.Diabetes Care1980; 3: 299–324.
12.
MicossiP., BosiE., CristalloM.Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CS II).Acta Diabetol Lat1986; 23: 155–64.
13.
ScarpioniL., BallocchiS., CastelliA., ScarpioniR.Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis. Comparison of intraperitoneal and subcutaneous administrationPerit Dial Int1994; 14: 127–31.
14.
MykkanenL., KuusistoJ., HaffnerS.M.Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects.Arterioscler Thromb1994; 14: 518–26.
15.
ZavaroniI., BonoraE., PagliaraM.Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.N Engl J Med1989; 320: 702–6.
16.
TwardowskiZ.J.Insulin adsorption to peritoneal dialysis bags.Perit Dial Bull1983; 3: 113–16.
17.
JohnsonC.A., AmidonG., ReichertE., PorterW.R.Ad sorption of insulin to the surface of peritoneal dialysis solution containers.Am J Kidney Dis1983; 3: 224–8.
18.
WideroeT.E., SmebyL.C., BergK.J.Intraperitoneal (125 I) insulin absorption during intermittent and continuous peritoneal dialysis.Kidney Int1983; 23: 22–8.
19.
PeetomJ.J., WillekensF.L.A., MeindersA.E.Absorption and biological effect of intraperitoneal insulin administration in patients with terminal renal failure treated by continuous ambulatory peritoneal dialysis (CAPD).Neth J Med1985; 28: 435–41.
20.
BalducciA., SlamaG., RottembourgJ.Intra-peritoneal insulin in uraemic diabetics undergoing continuous ambulatory peritoneal dialysis.Br Med J1981; 283: 1021–3.
21.
RottembourgJ., IssadB., AllouacheM.Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients.Perit Dial Int1989; 9: 289–94.
22.
BeardsworthS.F., AhmadR., TerryE., KarimK.Intraperitoneal insulin: A protocol for administration during CAPD and review of published protocols.Perit Dial Bull1988; 8: 145–51.
23.
SpottiD., SlavieroG., LaroccaE.Intermediary metabolism and glycemic control in insulin-dependent diabetic uremic patients treated by continuous peritoneal dialysis.Nephron1988; 49: 219–22.
24.
ShapiroD.J., BlumenkrantzM.J., LevinS.R., CoburnW.Absorption and action of insulin added to peritoneal dialysate in dogs.Nephron1979; 23: 174–80.
25.
KhannaR., OreopoulosD.G.Peritoneal dialysis in diabetic end stage renal disease.J Diabet Complications1989; 3: 12–17.
26.
KempermanF.A.W., VanleusenR., VanliebergenF.J.Continuous ambulatory peritoneal dialysis in patients with diabetic nephropathy.Neth J Med1991; 38: 236–45.
27.
LindbladA.S., NolphK.D., NowakJ.W.A survey of the NIH CAPD registry population with end-stage renal disease attributed to diabetic nephropathy.J Diabet Complications1988; 2: 227–32.
28.
KredietR.T., ZuyderhoudtF.M., BoeschotenE.W., AriszL.Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients.Nephron1986; 42: 133–40.
29.
ScarpioniL.L., PoisettiP.G., BallocchiS., BergonziG.Selective peritoneal protein loss.Contrib Nephrol1989; 70: 318–24.
BagdadeJ.D., DunnF.L.Effects of insulin treatment on lipoprotein composition and function in patients with IDDM.Diabetes1992; 41(Suppl 2): 107–10.
32.
RuotoloG., MicossiP., GalimbertiG.Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes.Metabolism1990; 39: 598–604.
33.
ManskeC.L., ThomasW., WangY., WilsonR.F.Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup.Kidney Int1993; 44: 617–21.
